Introduction: Long-term Safety of Canagliflozin in Type 2 Diabetes

Canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, has been a mainstay in the management of type 2 diabetes since its FDA approval in 2013. By blocking glucose reabsorption in the proximal renal tubule, it reduces hyperglycemia and provides well-documented cardiorenal benefits. However, as with any medication intended for chronic use, the long-term safety profile must be rigorously characterized. This analysis synthesizes evidence from landmark trials, real-world data, and regulatory updates to guide clinicians in risk-benefit assessment over years of therapy. With accumulating experience from the CANVAS program, CREDENCE trial, and large observational cohorts, the safety landscape has become clearer, enabling personalized prescribing and monitoring strategies.

Mechanism of Action and Therapeutic Role

Canagliflozin selectively inhibits SGLT2, the primary transporter responsible for reclaiming approximately 90% of filtered glucose. The resulting glycosuria lowers plasma glucose independently of insulin secretion, making it effective across the spectrum of type 2 diabetes. The drug also induces mild osmotic diuresis and natriuresis, which contribute to its cardiovascular and renal benefits. Initial approval covered doses of 100 mg and 300 mg daily; later indications expanded to include chronic kidney disease (CKD) with albuminuria and heart failure with reduced ejection fraction (HFrEF). Understanding these mechanisms is essential for interpreting long-term safety signals, including volume depletion, electrolyte disturbances, and effects on bone metabolism. Additionally, the dual inhibition of SGLT2 and partial SGLT1 in the intestine may confer postprandial glucose reduction and influence gut hormone release, further distinguishing canagliflozin from other agents in the class.

Cardiovascular Safety: Evidence from Controlled Trials and Real-World Studies

CANVAS Program

The CANVAS (Canagliflozin Cardiovascular Assessment Study) and CANVAS-R trials, enrolling over 10,000 patients, demonstrated a significant reduction in the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke (MACE) with canagliflozin compared to placebo (hazard ratio 0.86; 95% CI 0.75–0.97). Extended follow-up did not reveal an increase in all-cause mortality. However, the CANVAS program identified an increased risk of lower-limb amputations, leading to an FDA boxed warning. In long-term follow-up, amputation rates remained higher with canagliflozin (approximately 5.9 versus 3.4 events per 1000 patient-years), with the greatest risk in patients with prior amputation, peripheral vascular disease, or on the 300 mg dose. Absolute risk in low-risk patients remains small, and the mechanism may involve altered tissue perfusion and impaired angiogenesis. Subgroup analyses suggest that the cardiovascular benefit is consistent across age, sex, and baseline renal function.

Heart Failure Outcomes

One of the most clinically significant long-term benefits is the reduction in heart failure hospitalizations. In CANVAS, canagliflozin reduced the composite of cardiovascular death or hospitalization for heart failure by 22% (HR 0.78; 95% CI 0.67–0.91). This benefit emerged early and persisted for the duration of follow-up. Real-world studies from the SGLT2 inhibitor class confirm a 30–40% reduction in heart failure events, and canagliflozin is now indicated for HFrEF regardless of diabetes status. When assessing long-term safety, the favorable effect on volume status and ventricular function should be weighed against potential risks such as volume depletion in patients on high-dose loop diuretics.

CREDENCE Trial

The CREDENCE trial specifically evaluated canagliflozin in 4401 patients with type 2 diabetes and CKD (eGFR 30–90 mL/min/1.73 m²). Over a median follow-up of 2.6 years, canagliflozin reduced the primary renal composite outcome (end-stage kidney disease, doubling of serum creatinine, or renal death) by 30% (HR 0.70; 95% CI 0.59–0.82). Cardiovascular outcomes were consistent with CANVAS, with no new safety signals. Long-term extension studies confirm durability of renal benefit without additional adverse effects, provided careful volume management. Notably, the risk of hyperkalemia was lower in the canagliflozin group than in placebo, likely due to enhanced kaliuresis from increased distal tubular flow.

Real-World Evidence

Data from large observational studies, including the Observational Medical Outcomes Partnership, have generally corroborated trial findings. Real-world cohorts show no increase in serious adverse events such as major bleeding or arrhythmias, and they reinforce the cardiovascular and renal benefits seen in clinical trials. However, these analyses also confirm the elevated amputation risk in patients with peripheral artery disease, highlighting the need for careful patient selection. European registries further indicate that the incidence of genital infections is highest in the first six months and then declines, supporting a strategy of early monitoring and proactive management.

Renal Effects: Protection versus Potential Harm

Canagliflozin’s long-term renal safety is a balance of robust nephroprotection and manageable risks. Acute kidney injury (AKI) has been reported, particularly in patients with intravascular volume depletion, concurrent loop diuretic use, or underlying renal artery stenosis. In clinical trials, AKI incidence was below 1% and not significantly different from placebo. The characteristic initial dip in eGFR (~5 mL/min/1.73 m²) during the first few weeks reflects hemodynamic changes rather than structural injury; after stabilization, eGFR decline is slowed compared to placebo. This “hemodynamic dip” is reversible upon discontinuation and should not prompt premature cessation. The drug is contraindicated when eGFR is below 30 mL/min/1.73 m² (or below 45 mL/min/1.73 m² for initiation of the 300 mg dose). Regular monitoring of electrolytes and creatinine at baseline, at 3–6 months, and annually is recommended to mitigate hyperkalemia and dehydration risks.

Electrolyte and Volume Management

Chronic diuresis can cause mild dilutional hyponatremia, especially in elderly patients or those with low sodium intake. The glucose-induced osmotic diuresis may also predispose to volume depletion and orthostatic hypotension. In practice, gentle fluid resuscitation is advised when managing dehydration in canagliflozin users. Long-term studies have not found a significant increase in severe electrolyte abnormalities, but vigilance remains warranted, particularly during intercurrent illness or hot weather. Potassium levels should be monitored, as canagliflozin may reduce serum potassium through increased distal tubular flow; however, severe hypokalemia is uncommon. Combined use with RAAS inhibitors appears safe and may even lower hyperkalemia risk compared to placebo, a distinct advantage in cardiorenal protection.

Renal Safety in Special Populations

Elderly patients and those with polypharmacy require particular attention. In patients aged 75 and older, the risk of volume depletion and falls is higher, but the absolute benefit in heart failure and renal preservation remains substantial. Starting at the 100 mg dose and titrating based on tolerance is reasonable. For patients with advanced CKD (eGFR 15–30 mL/min/1.73 m²), canagliflozin is not recommended for glycemic control, but recent evidence suggests continued renal protection when used for HFrEF, with careful monitoring of electrolytes and fluid status. The DAPA-CKD and EMPA-KIDNEY trials have extended the class benefits to nondiabetic kidney disease, but canagliflozin-specific data in nondiabetic CKD are awaited.

Bone Health and Fracture Risk

The CANVAS program reported an increased incidence of fractures, especially of the upper limbs (hazard ratio 1.26; 95% CI 1.04–1.52). This finding was not replicated in the CREDENCE trial or in meta-analyses of all SGLT2 inhibitors. The mechanism may involve changes in calcium-phosphate metabolism: SGLT2 inhibition increases serum phosphate, leading to mild elevations in parathyroid hormone and potential bone turnover. Additionally, the osmotic diuresis may cause small losses of calcium and magnesium, further influencing bone metabolism. In clinical practice, bone density should be assessed at baseline in patients at risk for osteoporosis (postmenopausal women, men over 70, history of fragility fracture). For patients with existing osteoporosis or prior fracture, alternative SGLT2 inhibitors such as empagliflozin or dapagliflozin may be preferred, as they have not shown a fracture signal in their respective trials. The absolute risk difference with canagliflozin is small—approximately 0.7 additional fractures per 1000 patient-years—so shared decision-making is appropriate. Long-term dual-energy X-ray absorptiometry (DEXA) follow-up every 1–2 years can be considered in high-risk patients. Supplementation with vitamin D and calcium should be optimized.

Adverse Events: Genital Infections, Urinary Tract Infections, Ketoacidosis, and Amputation

Genitourinary Infections

Genital mycotic infections are the most common side effect, occurring in 8–10% of women and 6–8% of men in clinical trials, with a dose-dependent relationship. Long-term use does not appear to increase incidence beyond the first few months; infections are typically mild and respond to topical antifungals. Recurrent infections may require temporary discontinuation or dose reduction. Patient education on hygiene and symptom recognition is essential. For men with recurrent balanitis, circumcision may be considered in refractory cases. The risk of Fournier gangrene, although exceedingly rare (incidence <0.01%), requires prompt recognition and referral if symptoms such as perineal pain, swelling, or crepitus develop. Public awareness campaigns have reduced delays in diagnosis.

Urinary Tract Infections

Although some SGLT2 inhibitors have been linked to increased UTIs, canagliflozin trials have not consistently shown a significant rise in serious infections. However, the incidence of pyelonephritis is higher compared to placebo, particularly in women with recurrent UTIs. Long-term data from the DISCOVER study indicate that UTI-related hospitalization remains low (approximately 0.3% per year). Patients with recurrent UTIs should be monitored, and an alternative class may be considered if infections persist. Urine cultures should be obtained before initiating treatment in patients with a history of complicated UTIs, and any signs of ascending infection warrant early antibiotic therapy.

Euglycemic Diabetic Ketoacidosis (DKA)

Euglycemic DKA is a rare but serious adverse event, with an incidence of approximately 0.1–0.2% per year in long-term trials. It can occur with near-normal glucose levels, often triggered by illness, fasting, surgery, or alcohol excess. Patients on insulin-pump therapy or those with reduced beta-cell function are at higher risk. Long-term use requires ongoing education about sick-day rules and "stop" criteria (e.g., vomiting, infection, pending surgery). The FDA labeling recommends testing for ketones if DKA symptoms arise, even without hyperglycemia. Awareness of this condition is critical for early intervention. Clinicians should advise patients to temporarily discontinue canagliflozin during prolonged fasting, severe intercurrent illness, or before elective surgery, and to resume only after recovery and with medical guidance. The use of point-of-care ketone meters for at-home monitoring can empower patients and reduce diagnostic delays.

Lower-Limb Amputation Risk

The FDA boxed warning regarding lower-limb amputations was based on CANVAS data. In long-term follow-up of CANVAS and real-world analyses, the risk remains elevated in patients with peripheral arterial disease and prior amputation, but not in those without these risk factors. The mechanism is speculative but may involve altered wound healing due to diuresis-induced tissue hypoperfusion or impaired angiogenesis. A thorough vascular assessment is recommended before starting canagliflozin, and any new foot pain, ulceration, or infection warrants prompt podiatric evaluation. For high-risk patients, alternative SGLT2 inhibitors such as empagliflozin or dapagliflozin are often preferred. Risk mitigation strategies include regular foot inspections, proper footwear, smoking cessation, and multidisciplinary care. The absolute risk for low-risk patients remains low, and for many the cardiovascular and renal benefits outweigh this adverse event.

Monitoring Strategies for Long-Term Safety

Safe, long-term use of canagliflozin requires a structured monitoring plan. Key elements include:

  • Renal function: Check eGFR and serum creatinine at baseline, after 3–6 months, and annually. Discontinue if eGFR falls persistently below 30 mL/min/1.73 m². If a decline >30% occurs within the first few months, evaluate for volume depletion or concomitant nephrotoxic drug use.
  • Electrolytes: Measure sodium, potassium, magnesium at baseline and during acute illness. Consider supplementation if levels are borderline low. Monitor for hyperkalemia when used with RAAS inhibitors; canagliflozin may actually reduce incidence.
  • Volume status: Assess for orthostatic symptoms, pedal edema, and excessive thirst. Adjust concomitant diuretics or antihypertensives as needed. Advise patients to maintain adequate oral fluid intake, especially in hot weather or during exercise.
  • Bone density: Perform DEXA scan at baseline in high-risk patients (postmenopausal women, men >70, low-trauma fracture history); repeat every 1–2 years if risk factors persist. Evaluate calcium and vitamin D status.
  • Foot care: Instruct daily inspection, proper footwear, and avoidance of barefoot walking. Refer to podiatrist if peripheral neuropathy or vascular disease is present. Consider biannual foot exams by a specialist.
  • Ketone awareness: Educate to recognize DKA symptoms (nausea, abdominal pain, deep breathing) and to test for ketones when ill or after extended fasting. Provide a written sick-day plan, and consider giving a ketone meter to high-risk patients.

For patients developing recurrent genital infections, switching to a different SGLT2 inhibitor (e.g., empagliflozin, which has a lower incidence in some studies) or reducing to the 100 mg dose may be considered. The 300 mg dose is associated with more adverse events without a consistent incremental glycemic advantage, so reserving it for patients who require additional glycemic lowering after maximal doses of metformin and other agents is prudent.

Comparative Safety: Canagliflozin versus Other SGLT2 Inhibitors

Canagliflozin shares many long-term safety characteristics with empagliflozin and dapagliflozin, but important differences exist. Empagliflozin’s EMPA-REG OUTCOME trial showed a 38% reduction in cardiovascular death without an increase in amputations, possibly due to its higher selectivity for SGLT2 over SGLT1. Dapagliflozin’s DECLARE-TIMI 58 trial enrolled a lower baseline risk population and did not find a fracture signal. Canagliflozin’s greater potency for glycosuria may contribute to its higher rates of genital infections and amputations in head-to-comparisons. A network meta-analysis published in Diabetologia (PMID: 31664436) concluded that canagliflozin has the most robust data for renal outcomes but also the highest risk of lower-limb amputations. For patients with peripheral artery disease or prior amputation, an alternative agent such as empagliflozin or dapagliflozin is generally recommended. In patients with HFrEF and CKD, canagliflozin remains a first-line choice due to its strong evidence base, but clinicians should weigh the amputation risk against the unique renal benefits. The FDA safety communication provides additional context for clinical decision-making. Head-to-head randomized trials directly comparing SGLT2 inhibitors are limited, but real-world studies suggest that class switching from canagliflozin to empagliflozin or dapagliflozin may reduce amputation risk in susceptible patients without losing cardiorenal benefits.

Long-Term Patient Perspectives and Adherence

Adherence to canagliflozin over years is influenced by side effects and perceived benefits. Genital infections can be embarrassing and lead to discontinuation if not managed proactively. Patient education about self-treatment with over-the-counter antifungals and the likely resolution over time improves persistence. Financial considerations, including insurance coverage and copay assistance programs, also affect long-term use. In some healthcare systems, canagliflozin is preferred over other SGLT2 inhibitors because of cost or formulary status. Clinicians should review adherence at each visit, reinforce the mechanism of benefit, and address any concerns regarding rare but serious events without causing undue alarm. Shared decision-making that incorporates patient values, lifestyle factors, and comorbidity burden is central to optimizing outcomes.

Conclusion: Integrating Safety into Clinical Practice

Canagliflozin remains a valuable option for patients with type 2 diabetes and established cardiovascular disease, CKD, or heart failure. Its long-term safety profile is well defined, with risks that are predictable and generally manageable. The benefits—particularly in reducing heart failure hospitalizations and slowing renal disease progression—typically outweigh the absolute risks of fractures, genital infections, and amputation in appropriately selected patients. Careful monitoring, patient education, and individualized risk stratification allow clinicians to maximize therapeutic outcomes while minimizing adverse events. As real-world data continue to accumulate from registries and observational studies, the long-term safety perspective will further refine clinical guidelines. For now, canagliflozin stands as proof that SGLT2 inhibition can be both effective and safe over years of use when integrated into a comprehensive diabetes management plan. Ongoing research into its use in nondiabetic populations and novel indications will continue to shape its place in therapy, but the foundation of safety established over the past decade supports confident prescribing with appropriate vigilance.